Zobrazeno 1 - 8
of 8
pro vyhledávání: '"329"'
Autor:
U. Creutzig, P. Smisek, L. Hovi, B. Stark, B. Gibson, B. Razzouk, Carmelo Rizzari, R. Tamminga, G.J.L. Kaspers, A. Baruchel, S. Ha, D. Reinhardt, Y. Bertrand, M. Zimmermann, H. Armendariz, Alexei Maschan, M. Dworzak, O. Smith
Publikováno v:
Blood. 112:2977-2977
Relapse remains the commonest adverse event in newly diagnosed AML patients, and the reported long-term survival after relapse in pediatric AML is 20–30%. Allogeneic stem cell transplantation (allo-SCT) in CR1 is employed by several groups with the
Autor:
Shanta Chawla, Manuel Modiano, Jayaram S. Bharadwaj, Jawad Francis, Hlalah Osama, Lee S. Schwartzberg, Nishan Tchekmedyian, Francois Lebel, Gajanan Bhat
Publikováno v:
Blood. 136:34-35
Background: Eflapegrastim (Rolontis®, Efla) is a long-acting granulocyte-colony stimulating factor (G-CSF), consisting of a recombinant human G-CSF analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. Efla is not a b
Autor:
Erin Morris, John S. Holcenberg, F. Leonard Johnson, Stanton Goldman, Raymond J. Hutchinson, Jerry Z. Finklestein, Susan G. Kreissman, Elizabeth Harvey, Conrad Tou, Mitchell S. Cairo
Publikováno v:
Blood. 97:2998-3003
Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uric acid to a 5 times increased urine soluble product, allantoin
Autor:
Kimberly B. Dahlman, Megan L. Hames, Mahsa S. Talbott, Judy P. Tsai, Wade T. Iams, Nishitha Reddy, Kristy L. Richards
Publikováno v:
Blood. 124:4438-4438
Background: The use of lenalidomide is expanding to include patients with refractory or relapsed diffuse large B cell lymphoma (DLBCL). Lenalidomide is less toxic than thalidomide, but it leads to hypothyroidism in approximately 5-10% of patients tha
Autor:
Markus Loeffler, Norbert Schmitz, Randy D. Gascoyne, Roopesh Kansara, Michael Pfreundschuh, Bertram Glass, Samira Zeynalova, Kerry J. Savage, David Scott, Diego Villa, Laurie H. Sehn, Joseph M. Connors, Maike Nickelsen, Marita Ziepert
Publikováno v:
Blood. 124:394-394
[Graphic][1] Introduction : Despite the improvement of outcome of aggressive B-cell lymphomas in the rituximab treatment era, central nervous system (CNS) relapse continues to pose a significant management problem. It remains a challenge to select pa
Autor:
Heinz Haverkamp, Peter Borchmann, Jana Markova, Zdenek Kral, Andreas Engert, Carsten Kobe, Hans Theodor Eich, Josée M. Zijlstra, Anthony D. Ho, Harald Stein, Rolf-Peter Müller, Christoph Renner, Markus Dietlein, Volker Diehl
Publikováno v:
Blood. 118:589-589
Abstract 589FN2 Purpose: Intensified chemotherapy with eight cycles of BEACOPPescalated in advanced stage Hodgkin lymphoma (HL) is highly effective but also associated with relevant treatment related toxicity. In addition, the need for radiotherapy i
Autor:
John A. Liu Yin, Lars Kjeldsen, Robert Kerrin Hills, Brenda Gibson, Alan Kenneth Burnett, Donald Milligan, Ann Hunter, Archie G. Prentice, Anthony H. Goldstone, Keith Wheatley, Nigel H. Russell
Publikováno v:
Blood. 114:484-484
Abstract 484 On behalf of the NCRI AML Working Group, United Kingdom There is a general acceptance that survival in younger patients (75% relapse remains a problem. Optimisation of induction and defining the schedule and duration of post-induction ch
Autor:
Lisa Rybicki, Brian J. Bolwell, Ronald Sobecks, Elizabeth Kuczkowski, Stacey Brown, Steven Andresen, Matt Kalaycio, Brad Pohlman
Publikováno v:
Blood. 106:1764-1764
Many high-dose chemotherapy preparative regimens include agents known to cause pulmonary toxicity such as BCNU. Chemotherapy induced pulmonary toxicity may be fatal. From 1/1/93 to 12/31/04 we treated 533 NHL patients with oral busulfan 14mg/kg, VP-1